GSK tops the Access to Medicines Index for the fifth consecutive time.
These press releases are intended for business journalists and analysts/investors
GSK Consumer Healthcare announced that it will close its manufacturing facility at Ermington, in Sydney’s north-west, in 2020. The decision was made after a thorough evaluation of the site, which revealed the manufacturing site would not be able to remain competitive in the long-term.
All entitlements are protected for the 223 employees whose jobs are affected, and the company will work through the next four years to provide support.
GSK invests in Victorian manufacturing with Monash and the Victorian Government as founding partner of the Medicines Manufacturing Innovation Centre.
GSK prioritises whooping cough vaccine availability for those most at risk of the disease and confirms uninterrupted supply of Boostrix® and Boostrix® IPV to all Australian State, Territory and Federal Government vaccination programs where Boostrix/Boostrix-IPV is the vaccine of choice.
GSK publishes Medicines Australia transfer of value report
• Leading lifestyle commentator Shelly Horton reveals hay fever struggle
• Over 3 million Australians could be affected by hay fever season
• Up to 8 in 10 people with asthma also affected by hay fever
We are one of the world’s largest science-led pharmaceutical and healthcare companies. Each year we research, manufacture and sell innovative medicines, vaccines and healthcare products for millions of people across the world, helping them to do more, feel better and live longer.